Imperial College London
Portrait Picture

Professor Eduardo Olavarria

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Practice (Stem Cell Transplantation & Cellular)
 
 
 
//

Contact

 

+44 (0)20 3313 4017e.olavarria Website

 
 
//

Location

 

4N5Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

  1. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing AMJ, Lee H, Grant P, Nastouli E, Lambert J, Pace M, Salasc F, Monit C, Innes AJ, Muir L, Waters L, Frater J, Lever AML, Edwards SG, Gabriel IH, Olavarria E. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019 Apr;568(7751):244-248
  2. Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-Martin J, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, I YA, Chalandon Y, Kroger N. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018 Nov 5.
  3. Lozano Cerrada S, Altaf SY, Olavarria E. Allogeneic stem cell transplantation from unrelated donors in acute leukaemia. Curr Opin Oncol. 2018 Nov;30(6):418-424.
  4. Hanley BP, Yebra-Fernandez E, Palanicawandar R, Olavarria E, Naresh KN. Lineage switch from acute myeloid leukemia to T cell/myeloid mixed phenotype acute leukemia: First report of an adult case. Am J Hematol. 2018 Dec;93(12):E395-E397
  5. McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. Br J Haematol. 2018 May 29
  6. Beckerson J, Szydlo RM, Hickson M, Mactier CE, Innes AJ, Gabriel IH, Palanicawandar R, Kanfer EJ, Macdonald DH, Milojkovic D, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlu J. Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. Clin Nutr. 2018 Mar 28. pii: S0261-5614(18)30120-1
  7. Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF. Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188.
  8. Ciáurriz M, Beloki L, Zabalza A, Bandrés E, Mansilla C, Pérez-Valderrama E, Lachén M, Rodríguez-Calvillo M, Ramírez N, Olavarría E. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2017 Dec;19(6)
  9. Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017 Nov;92(11):1214-1223.
  10. Pavlů J, Auner HW, Szydlo RM, Sevillano B, Palani R, O'Boyle F, Chaidos A, Jakob C, Kanfer E, MacDonald D, Milojkovic D, Rahemtulla A, Bradshaw A, Olavarria E, Apperley JF, Pello OM. Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation. Bone Marrow Transplant. 2017 Dec;52(12):1599-1601
  11. Innes AJ, Lee M, Francis N, Olavarria E. Immunosuppression-associated Kaposi sarcoma following stem cell transplantation. Br J Haematol. 2017 Jul;178(1):9
  12. Pello OM, Innes AJ, Bradshaw A, Finn SA, Uddin S, Bray E, Olavarria E, Apperley JF, Pavlů J. BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. Eur J Haematol. 2017 Jan 13. doi: 10.1111/ejh.12848. [Epub ahead of print]
  13. Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2017 Jun;177(5):759-765
  14. Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 1;123(15):2875-2880
  15. Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF. An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2017 Oct;143(10):2059-2066
  16. Menter T, Medani H, Olavarria E, Kanfer E, Naresh KN. Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016 Dec 16.
  17. Patel A, Szydlo RM, Auner HW, Kanfer EJ, MacDonald DH, Milojkovic D, Altaf S, Innes A, Gabriel I, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlů J. C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality. Br J Haematol. 2016 Nov 29.
  18. Altaf SY, Apperley JF, Olavarria E. Matched unrelated donor transplants-State of the art in the 21st century. Semin Hematol. 2016 Oct;53(4):221-229
  19. Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, Iacobelli M, Niederwieser D, Olavarría E, Suarez F, Ruutu T, Verdonck L, Hume R, Nejadnik B, Lai C, Finetto G, Richardson P. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. Biol Blood Marrow Transplant. 2016 Oct;22(10):1874-82.
  20. Koenecke C, Heim D, van Biezen A, Heuser M, Aljurf M, Kyrcz-Krzemien S, Volin L, de Souza CA, Gedde-Dahl T, Sengeloev H, Schanz U, Komarnicki M, Arroyo CH, Tholouli E, Gluckman E, Esquirol A, Yakoub-Agha I, Gürman G, Olavarria E, Kröger N. Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplant. 2016 Apr 25.
  21. Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation EBMT. Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. Ann Hematol. 2016 May;95(6):967-72
  22. Ciáurriz M, Beloki L, Bandrés E, Mansilla C, Zabalza A, Pérez-Valderrama E, Lachén M, Ibáñez B, Olavarría E, Ramírez N. Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8 T cells by flow cytometry. Cytometry B Clin Cytom. 2016 Feb 26
  23. Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015 Nov;29(11):2126-33
  24. Kaplan A, Lindgren B, Marschner S, Aznar M, Zalba S, Sánchez P, Ayape ML, Olavarría E, Antelo ML. Evaluation of the platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days. Transfus Apher Sci. 2016 Apr;54(2):248-52
  25. Ciáurriz M, Zabalza A, Beloki L, Mansilla C, Pérez-Valderrama E, Lachén M, Bandrés E, Olavarría E, Ramírez N. The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients. Cell Mol Life Sci. 2015 Nov;72(21):4049-62
  26. Feliu J, Del Pozo JL, Azanza JR, García-Muñoz R, Zabalza A, Gorosquieta A, Pérez-Equiza E, Olavarría E. Antifungal prophylaxis with anidulafungin to minimize drug interactions with an antiepileptic treatment in a hematopoietic stem cell transplant recipient. J Clin Pharm Ther. 2015 Jun 13.
  27. Antelo ML, Zabalza A, Sánchez Antón MP, Zalba S, Aznar M, Mansilla C, Ramírez N, Olavarría E. Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®). J Clin Apher. 2016 Feb;31(1):48-52
  28. Beloki L, Ciaurriz M, Mansilla C, Zabalza A, Perez-Valderrama E, Samuel ER, Lowdell MW, Ramirez N, Olavarria E. Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood. J Transl Med. 2015 May 20;13:165.
  29. Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? Biol Blood Marrow Transplant. 2015 Jul;21(7):1230
  30. Beloki L, Ciaurriz M, Mansilla C, Zabalza A, Perez-Valderrama E, Samuel ER, Lowdell MW, Ramirez N, Olavarria E. CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers. J Transl Med. 2014 Nov 19;12:317.
  31. Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, Poiré X, Kobbe G, Narni F, Cortelezzi A, Olavarría E, Schmitz N, Sureda A, Dreger P. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014 Oct 10;32(29):3347-8.
  32. Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E; (EBMT). Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the CMWP of the EBMT. Haematologica. 2014 Sep;99 (9):1492-8.
  33. Beloki L, Ramírez N, Olavarría E, Samuel ER, Lowdell MW. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors. Cytotherapy. 2014 Oct;16(10):1390-408
  34. Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5.
  35. Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G, Chevallier P, Cahn JY, Legrand F, Rovira M, Passweg J, Sierra J, Nguyen S, Maillard N, Yakoub-Agha I, Linkesch W, Cannell P, Marcatti M, Bay JO, Chalandon Y, Kröger N, Gluckman E, Rocha V, Olavarria E, Ruggeri A; Eurocord and CMWP-EBMT. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2014 Nov;20(11):1841-6.
  36. Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, De Witte T, Olavarria E, Kröger N. Allogenic hematopoietic stem cell transplantation in patients with polycythemia or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: report from the MPN subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Haematologica. 2014 May;99(5):916-21
  37. Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn JY, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014 Feb;20(2):279-81.
  38. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the CIBMTR. Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97.
  39. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 5;122(24):3863-70.
  40. Ramírez N, Beloki L, Ciáurriz M, Rodríguez-Calvillo M, Escors D, Mansilla C, Bandrés E, Olavarría E. The abrogation of TCR-independent interactions with human serum ensures a selective capture of therapeutic virus-specific CD8 T-cells by Multimer Technology in Adoptive Immunotherapy. J Immunol Methods. 2013 Oct 31;396(1-2):168-72.
  41. Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 Aug 1;369(5):438-47.
  42. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013. 121, 4439-4442..
  43. Ramírez N, Beloki L, Ciaúrriz M, Rodríguez-Calvillo M, Escors D, Mansilla C, Bandrés E, Olavarría E. Impact of T cell selection methods in the success of clinical adoptive immunotherapy. Cell Mol Life Sci. 2013 Epub ahead of print]
  44. Beloki L, Ciáurriz M, Mansilla C, Bandrés E, Rodríguez-Calvillo M, Ramírez N, Olavarría E. The abrogation of TCR-independent interactions with human serum ensures a selective capture of therapeutic virus-specific CD8 T-cells by multimer technology in Adoptive Immunotherapy. J Immunol Methods. 2013 Oct 31; 396(1-2):168-72.
  45. Zabalza A, Gorosquieta A, Equiza EP, Olavarria E. Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review. Ther Adv Hematol. 2013 Jun;4(3):217-30.
  46. Ramírez N, Olavarría E. Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies. Bone Marrow Transplant. 2013 Oct;48(10):1265-70.
  47. Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011; 118 (17) 5697-5700